May 05–07, 2024 | Buck Institute for Research on Aging, Novato, CA, United States
Scientific Organizers:
Bei B. Zhang and Teresa Zimmers

-
Scientific Organizers: Bei B. Zhang and Teresa Zimmers
Bei B. Zhang
Teresa Zimmers
***Meeting program subject to change.
Available Formats: = In PersonMerchandise Options
Registration Options
Fundraising
Booking Function
Fundraising
Sunday, May 5, 2024
Monday, May 6, 2024
NovoNordisk
Oregon Health and Science University
Session Chair
Session Chair
Clinical Classification of Cancer Cachexia
Cardiac Dysfunction and Wasting at the Heart of Cachexia
Insights Into Lung Cancer-Associated Cachexia From the TRACERx Study
Contribution and Therapeutic Prospects from the Gut Microbiome to Cancer Cachexia
Session Chair
Session Chair
Organ Crosstalk in Cachexia
Energy Metabolism in Cachexia - Quantitative Fluxomics
Muscle Microenvironment in Cancer Cachexia
Short Talk: Short Talk: Impaired cAMP/CREB1 Signaling Drives Mitochondrial Dysfunction in Skeletal Muscle During Cancer Cachexia
Short Talk: Short Talk: Cancer Cachexia Causes Impaired CD8+ T Cell Activation and Lymphopenia that Contributes to Tissue Wasting
Tuesday, May 7, 2024
Session Chair
Session Chair
Cachexia and Cancer
Persistent Inflammatory/Immunosuppressive Catabolic Syndrome (PICS) after Sepsis
Cachexia and COVID-19
Adipose Tissue Role in Acute COVID-19 and Long COVID Syndrome: A New Form of Cachexia?
Short Talk: Short Talk: Systemic Metabolic and Immune Defects in Advanced Cancer Patients Prior to the Onset of Pre-Cachexia
Short Talk: Short Talk: Vagal Perturbation of the Liver-Brain Axis Deters Cancer-Associated Cachexia Independent of Tumor Burden
Session Chair
Session Chair
Chronic Cardiac Wasting-Associated Cardiomyopathy in Post-Tumor-Mediated Cancer Cachexia
D2-HG Promotes IDH-Mutant Cancer-Associated Autophagic Proteolysis Skeletal Muscle
Efficacious and Durable Myostatin Knockdown Using Chemically Optimized siRNAs
Deaf1 Regulates Muscle Regeneration through Autophagy
Roles of HIF2 and PTHLH in Kidney Cancer-Associated Cachexia: Treatment with a First-In-Class Agent
Systemic Physiological Changes Indicative of Cancer Cachexia at Diagnosis
Targeting Skeletal Muscle Lipid Hydroperoxides in Cancer Cachexia
PDAC Recovery Associates with Impaired Hepatic metabolism, Delayed Muscle Recovery, and Decreased Activity Levels
Session Chair
Session Chair
Digital Technology for Body Weight Phenotyping
Harnessing Cachexia Mechanisms to Elucidate Tumor-directed Therapies
GDF15/Ponsegromab: A Potential Treatment for Cachexia
Short Talk: Short Talk: A Phase 1b Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients (pts) with Cachexia and Elevated GDF-15 Levels
Short Talk: Short Talk: Nozomitumab: A Potential Treatment for Prevention of Cancer-Induced Cachexia via Reprogramming Macrophage Function in Adipose and Muscle Tissues
Subscribe for Updates